[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
January 24, 2011

Analytical Issues Regarding Rosiglitazone Meta-analysis

Author Affiliations

Author Affiliations: Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.

Arch Intern Med. 2011;171(2):179-180. doi:10.1001/archinternmed.2010.508

We read with great interest the recently published article by Nissen and Wolski,1 which updated their previous meta-analysis2 of risk for myocardial infarction and cardiovascular mortality relating to the diabetes drug rosiglitazone. The authors conclude that rosiglitazone statistically significantly increases risk of myocardial infarction relative to comparators by reporting an odds ratio of 1.28, with a 95% confidence interval (CI) of 1.02 to 1.63 and a significant P value of .04, while finding no significant difference in cardiovascular mortality (P = .86 in their current analysis, compared with P = .06 in their previous report).

First Page Preview View Large
First page PDF preview
First page PDF preview